Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1377-1384

  Sato, Tadashi ^a   Suzuki, Yohei ^a   Mori, Takanori ^a   Maeda, Masahiro ^b   Abe, Masaaki ^a   Hino, Okio ^a   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Area under the curve; Biomarker; ELISA; N ERC mesothelin; Pleural mesothelioma

Indexed keywords

MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16K16; MONOCLONAL ANTIBODY 20A2; MONOCLONAL ANTIBODY 7E7; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PLASMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; PLEURAL NEOPLASMS; PROCEDURES; STANDARDS;

ENZYME-LINKED IMMUNOSORBENT ASSAY; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84991442203     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.297     Document Type: Article

References (28)

1. Sugarbaker, D. J., R. M. Flores, M. T. Jaklitsch, W. G. Richards, G. M Strauss, J. M. Corson, et al. 1999. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thor. Cardiovas. Surg. 117:54-63; discussion 63-5.
2. Vogelzang, N. J., J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2636-2644.
3. Krug, L. M., H. I. Pass, V. W. Rusch, H. L. Kindler, D. J. Sugarbaker, K. E. Rosenzweig, et al. 2009. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27:3007-3013.
4. Van Schil, P. E., P. Baas, R. Gaafar, A. P. Maat, M. Van de Pol, B. Hasan, et al. 2010. European Organisation for R, Treatment of Cancer Lung Cancer G. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. The. Eur. Respir. J. 36:1362-1369.
5. Bonfrer, J. M., J. H. Schouwink, C. M. Korse, and P. Baas. 1997. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res. 17:2971-2973.
6. Hedman, M., H. Arnberg, J. Wernlund, H. Riska, and O. Brodin. 2003. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 23:531-536.
7. Welker, L., M. Muller, O. Holz, E. Vollmer, H. Magnussen, and R. A. Jorres. 2007. Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 450:455-461.
8. Creaney, J., I. van Bruggen, M. Hof, A. Segal, A. W. Musk, N. de Klerk, et al. 2007. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 132:1239-1246.
9. Pass, H. I., D. Lott, F. Lonardo, M. Harbut, Z. Liu, N. Tang, et al. 2005. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 353:1564-1573.
10. Grigoriu, B. D., A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, et al. 2007. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 13:2928-2935.
11. Robinson, B. W., J. Creaney, R. Lake, A. Nowak, A. W. Musk, N. de Klerk, et al. 2003. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612-1616.
12. Robinson, B. W., J. Creaney, R. Lake, A. Nowak, A. W. Musk, N. de Klerk, et al. 2005. Soluble mesothelin-related protein-a blood test for mesothelioma. Lung cancer 49(Suppl. 1):S109-S111.
13. Hassan, R., A. T. Remaley, M. L. Sampson, J. Zhang, D. D. Cox, J. Pingpank, et al. 2006. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 12:447-453.
14. Scherpereel, A., B. Grigoriu, M. Conti, T. Gey, M. Gregoire, M. C. Copin, et al. 2006. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 173:1155-1160.
15. Hino, O., E. Kobayashi, M. Nishizawa, Y. Kubo, T. Kobayashi, Y. Hirayama, et al. 1995. Renal carcinogenesis in the Eker rat. J. Cancer Res. Clin. Oncol. 121:602-605.
16. Yamashita, Y., M. Yokoyama, E. Kobayashi, S. Takai, and O. Hino. 2000. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem. Biophys. Res. Commun. 275:134-140.
17. Hino, O. 2004. Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr. Mol. Med. 4:807-811.
18. Hassan, R., T. Bera, and I. Pastan. 2004. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10:3937-3942.
19. Shiomi, K., H. Miyamoto, T. Segawa, Y. Hagiwara, A. Ota, M. Maeda, et al. 2006. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 97:928-932.
20. Shiomi, K., Y. Hagiwara, K. Sonoue, T. Segawa, K. Miyashita, M. Maeda, et al. 2008. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin. Cancer Res. 14:1431-1437.
21. Li, Z. Q., T. Verch, and W. J. Allard. 2007. MESOMARK((R)) in vitro diagnostic test for mesothelioma. Expert Opin. Med. Diagn. 1:137-142.
22. Hollevoet, K., J. B. Reitsma, J. Creaney, B. D. Grigoriu, B. W. Robinson, A. Scherpereel, et al. 2012. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J. Clin. Oncol. 30:1541-1549.
23. Mundt, F., G. Nilsonne, S. Arslan, K. Csuros, G. Hillerdal, H. Yildirim, et al. 2013. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 8:e72030.
24. Pass, H. I., S. M. Levin, M. R. Harbut, J. Melamed, L. Chiriboga, J. Donington, et al. 2012. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N. Engl. J. Med. 367:1417-1427.
25. Ferro, P., P. A. Canessa, E. Battolla, P. Dessanti, M. C. Franceschini, L. Chiaffi, et al. 2013. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Anticancer Res. 33:2707-2713.
26. Tajima, K., M. Hirama, K. Shiomi, T. Ishiwata, M. Yoshioka, A. Iwase, et al. 2008. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res. 28:3933-3936.
27. Imashimizu, K., K. Shiomi, M. Maeda, N. Aoki, K. Igarashi, F. Suzuki, et al. 2011. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma. Exp. Ther. Med. 2:409-411.
28. Mori, T., K. Tajima, M. Hirama, T. Sato, K. Kido, S. Iwakami, et al. 2013. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J. Thorac. Dis. 5:145-148.